Want to see JP:4576 full AI Analyst Report?
4576 Stock Chart & Stats
¥105.00
-¥3.00(-1.74%)
At close: 4:00 PM EST
¥105.00
-¥3.00(-1.74%)
Day’s Range― - ―
52-Week Range¥66.00 - ¥181.00
Previous CloseN/A
Volume3.18M
Average Volume (3M)218.86K
Market Cap
¥5.01B
Enterprise Value¥3.25K
Total Cash (Recent Filing)¥1.54B
Total Debt (Recent Filing)¥594.17M
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.89
Shares Outstanding57,559,410
10 Day Avg. Volume270,440
30 Day Avg. Volume218,863
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.21
Price to Sales (P/S)11.87
P/FCF Ratio-9.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsStrong gross margins indicate that the underlying products can generate substantial contribution after direct costs. If revenue stabilizes and operating expenses are controlled, this margin structure could support meaningful operating leverage over time.
Improved Balance-Sheet LeverageLower leverage improves financial flexibility and reduces balance-sheet pressure while the company funds development activities. Although the balance sheet has been inconsistent, the latest improvement provides a stronger base for pursuing its pipeline.
Narrowing Losses And Lower Cash BurnThe improvement in losses and cash burn suggests progress toward better cost discipline, even though the company remains unprofitable and cash-flow negative. Sustaining this trend could extend its funding runway and reduce future financing dependence.
Bears Say
Persistent Operating And Net LossesDeep losses show that the current business scale is insufficient to cover operating and development costs. Until revenue expands materially or expenses decline, the company is unlikely to become self-sustaining and may require additional capital.
Negative Free Cash FlowPersistent cash burn limits internally generated funding for research, operations, and commercialization. Even with improvement in 2025, continued negative free cash flow creates ongoing financing risk and can dilute shareholders or increase liabilities.
Small And Volatile Revenue BaseA limited and unstable revenue base makes fixed-cost absorption difficult and leaves results highly dependent on product milestones or licensing activity. This volatility reduces earnings visibility and delays the path to sustainable profitability.
D.Western Therapeutics Institute News
4576 FAQ
What was D.Western Therapeutics Institute, Inc.’s price range in the past 12 months?
D.Western Therapeutics Institute, Inc. lowest stock price was ¥66.00 and its highest was ¥181.00 in the past 12 months.
What is D.Western Therapeutics Institute, Inc.’s market cap?
D.Western Therapeutics Institute, Inc.’s market cap is ¥5.01B.
When is D.Western Therapeutics Institute, Inc.’s upcoming earnings report date?
D.Western Therapeutics Institute, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 57 days.
How were D.Western Therapeutics Institute, Inc.’s earnings last quarter?
D.Western Therapeutics Institute, Inc. released its earnings results on Aug 13, 2026. The company reported -¥2.66 earnings per share for the quarter.
Is D.Western Therapeutics Institute, Inc. overvalued?
According to Wall Street analysts D.Western Therapeutics Institute, Inc.’s price is currently Overvalued.
Does D.Western Therapeutics Institute, Inc. pay dividends?
D.Western Therapeutics Institute, Inc. does not currently pay dividends.
What is D.Western Therapeutics Institute, Inc.’s EPS estimate?
D.Western Therapeutics Institute, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does D.Western Therapeutics Institute, Inc. have?
D.Western Therapeutics Institute, Inc. has 57,559,410 shares outstanding.
What happened to D.Western Therapeutics Institute, Inc.’s price movement after its last earnings report?
D.Western Therapeutics Institute, Inc. reported an EPS of -¥2.66 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of D.Western Therapeutics Institute, Inc.?
Currently, no hedge funds are holding shares in JP:4576
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
D.Western Therapeutics Institute, Inc.
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.